Tags : Futibatinib (TAS-120)


Taiho Oncology’s Futibatinib (TAS-120) Receives the US FDA’s Breakthrough Therapy

Shots: The designation is based on efficacy & safety results from the P-II FOENIX-CCA2 study involves assessing futibatinib (TAS-120) in patients with advanced cholangiocarcinoma. The findings will be presented at AACR 2021 The preliminary clinical evidence showed improvement on at least one clinical EPs over available therapy Futibatinib (TAS-120, PO) is a covalently-binding FGFR inhibitor […]Read More